Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 2, 2010, Pages 612-621

  Nickell, Justin R ^a   Krishnamurthy, Sairam ^a   Norrholm, Seth ^a   Deaciuc, Gabriela ^a   Siripurapu, Kiran B ^a   Zheng, Guangrong ^a   Crooks, Peter A ^a   Dwoskin, Linda P ^a  

^a University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROTETRABENAZINE; DOPAMINE TRANSPORTER; LOBELINE; METHAMPHETAMINE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG BINDING; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; ENZYME MECHANISM; IC 50; ISOMER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; STRUCTURE ACTIVITY RELATION; SYNAPSE VESICLE; SYNAPTOSOME;

3,4-DIHYDROXYPHENYLACETIC ACID; AMPHETAMINE-RELATED DISORDERS; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG EVALUATION, PRECLINICAL; LOBELINE; MALE; METHAMPHETAMINE; NICOTINIC AGONISTS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTIC VESICLES; SYNAPTOSOMES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 76749156644     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.160275     Document Type: Article

References (36)

1. 3H]dopamine from striatal slices. J Pharmacol Exp Ther 257: 262-270.
2. Briggs CA and McKenna DG (1998) Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists. Neuropharmacology 37:1095-1102.
3. Brown JM, Hanson GR, and Fleckenstein AE (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem 74:2221-2223.
4. Brown JM, Hanson GR, and Fleckenstein AE (2001) Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther 296:762-767.
5. Decker MW, Majchrzak MJ, and Arnerić SP (1993) Effects of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol Biochem Behav 45:571-576.
6. Di Chiara G and Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274-5278.
7. Dwoskin LP and Crooks PA (2002) A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol 63:89-98.
8. Eyerman DJ and Yamamoto BK (2005) Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter-2 immunoreactivity and monoamine depletions in the striatum. J Pharmacol Exp Ther 312:160-169.
9. Flammia D, Dukat M, Damaj MI, Martin B, and Glennon RA (1999) Lobeline: structure-affinity investigation of nicotinic acetylcholinergic receptor binding. J Med Chem 42:3726-3731.
10. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, and Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681-698.
11. Gold LH, Geyer MA, and Koob GF (1989) Neurochemical mechanisms involved in behavioral effects of amphetamines and related designer drugs. NIDA Res Monogr 94:101-126.
12. Harrod SB, Dwoskin LP, Crooks PA, Klebaur JE, and Bardo MT (2001) Lobeline attenuates d-methamphetamine self-administration in rats. J Pharmacol Exp Ther 298:172-179.
13. Harrod SB, Dwoskin LP, Green TA, Gehrke BJ, and Bardo MT (2003) Lobeline does not serve as a reinforcer in rats. Psychopharmacology (Berl) 165:397-404.
14. Hart CL, Ward AS, Haney M, Foltin RW, and Fischman MW (2001) Methamphetamine self-administration by humans. Psychopharmacology 157:75-81.
15. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
16. Liang NY and Rutledge CO (1982) Evidence for carrier-mediated efflux of dopamine from corpus striatum. Biochem Pharmacol 31:2479-2484.
17. Lim DY, Kim YS, and Miwa S (2004) Influence of lobeline on catecholamine release from the isolated perfused rat adrenal gland. Auton Neurosci 110:27-35.
18. Mantle TJ, Tipton KF, and Garrett NJ (1976) Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol 25:2073-2077.
19. + efflux from thalamic synaptosomes. Neuropharmacology 39:2654-2662.
20. Miller DK, Crooks PA, Teng L, Witkin JM, Munzar P, Goldberg SR, Acri JB, and Dwoskin LP (2001) Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J Pharmacol Exp Ther 296:1023-1034.
21. Miller DK, Crooks PA, Zheng G, Grinevich VP, Norrholm SD, and Dwoskin LP (2004) Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J Pharmacol Exp Ther 310:1035-1045.
22. Patel J, Mooslehner KA, Chan PM, Emson PC, and Stamford JA (2003) Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. J Neurochem 85:898-910.
23. Pifl C, Drobny H, Reither H, Hornykiewicz O, and Singer EA (1995) Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol 47: 368-373.
24. Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies. The DASIS Report - Primary Methamphetamine/ Amphetamine Admissions to Substance Abuse Treatment: 2005, 2008 Feb 7, SAMHSA, Rockville, MD. [Cited 2008 May 8] Available from: http://www.oas.samhsa. gov/2k8/methamphetamineTx/meth.htm.
25. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, and Ewing A (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15:4102-4108.
26. Sulzer D and Rayport S (1990) Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5:797-808.
27. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, and Uhl GR (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci U S A 94:9938-9943.
28. 3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J Neurochem 71:258-265.
29. Teng L, Crooks PA, Sonsalla PK, and Dwoskin LP (1997) Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake. J Pharmacol Exp Ther 280:1432-1444.
30. Terry AV Jr, Williamson R, Gattu M, Beach JW, McCurdy CR, Sparks JA, and Pauly JR (1998) Lobeline and structurally simplified analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine. Neuropharmacology 37:93-102.
31. 2+ current in cultured neurons from rat sympathetic ganglia. Eur J Pharmacol 363:75-80.
32. Wilhelm CJ, Johnson RA, Eshleman AJ, and Janowsky A (2008) Lobeline effects on tonic and methamphetamine-induced dopamine release. Biochem Pharmacol 75: 1411-1415.
33. Wise RA (2002) Brain reward circuitry: insights from unsensed incentives. Neuron 36:229-240.
34. Xu DD, Mo ZX, Yung KK, Yang Y, and Leung AW (2008) Individual and combined effects of methamphetamine and ketamine on conditioned place preference and NR1 receptor phosphorylation in rats. Neurosignals 15:322-331.
35. Yokel RA and Pickens R (1973) Self-administration of optical isomers of amphetamine and methylamphetamine by rats. J Pharmacol Exp Ther 187:27-33.
36. Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, and Crooks PA (2005) Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. J Med Chem 48:5551-5560.